NeoVentures Biotechnology Europe

At NeoVentures Biotechnology Europe, we’ve developed Aptamarker™, a next-generation proteomics platform that leverages NGS to complement traditional methods in Proteomics.

Objectives: - Co-development and Open Innovation projects http://neoventures-eu.com/

With Aptamarker™, you can:

• Detect protein epitopes—revealing conformations and post-translational modifications (PTMs) as they exist ex vivo.
• Expand your research scope without investing in new equipment, simply using standard NGS sequencing services and our Aptamarker™ analysis kits.
• Discover new diagnostic probes directly from our analysis of 268 million aptamer probes per sample, accelerating biomarker and target discovery.

 Why We Stand Out: 

✔ Unprecedented Biological Insight Aptamarker™ deciphers protein conformations, epitopes, and post-translational modifications (PTMs)—critical layers of biology that conventional proteomics misses, that are key for precision medicine. The future of proteomics isn’t incremental. It’s structural. We r_ewrite the rules of biological discovery, combining wet lab and in-silico analysis._

✔ Seamless Integration, Zero Infrastructure Burden No need for costly new instruments. Our plug-and-play kits leverage standard NGS workflows, turning existing platforms into powerhouses for high-resolution proteomic discovery. 

✔ Accelerating Discovery at Scale From biomarker identification, patient stratification to target validation, Aptamarker™ enables high-throughput screening with pharma-grade precision.